FDA Approves Trial for Intraoperative Image-Guided Cancer Surgery System

The trial is being funded by the US National Cancer Institute (NCI) as part of the NCI Experimental Therapeutics (NExT) program.

The Lumicell surgical system addresses the need to remove all cancer cells in the tumor bed, during the first surgery. The intraoperative detection system enables surgeons to find and remove residual cancer cells, in real-time, in the tumor bed.

W. David Lee, CEO of Lumicell, said, “Launching a feasibility study for intraoperative imaging of breast cancer during surgery is a critical next step for Lumicell. The NCI grant allows our team to demonstrate the efficacy of our system in reducing rates of positive margins and repeat surgeries. By enabling surgeons to remove sub-millimeter residual cancer, we expect to improve patient outcomes.”

Related Links:
Lumicell
MGH